KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity (2016 - 2025)

Historic Common Equity for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $117.6 million.

  • Rigel Pharmaceuticals' Common Equity rose 90355.97% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 90355.97%. This contributed to the annual value of $3.3 million for FY2024, which is 11147.88% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Common Equity stood at $117.6 million, which was up 90355.97% from $81.9 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Common Equity high stood at $117.6 million for Q3 2025, and its period low was -$31.8 million during Q3 2023.
  • In the last 5 years, Rigel Pharmaceuticals' Common Equity had a median value of -$3.7 million in 2022 and averaged $12.0 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Common Equity plummeted by 66461.79% in 2023, and later soared by 90355.97% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Common Equity stood at $30.4 million in 2021, then tumbled by 144.83% to -$13.6 million in 2022, then crashed by 110.37% to -$28.6 million in 2023, then soared by 111.48% to $3.3 million in 2024, then soared by 3476.92% to $117.6 million in 2025.
  • Its Common Equity stands at $117.6 million for Q3 2025, versus $81.9 million for Q2 2025 and $18.6 million for Q1 2025.